|Bid||42.63 x 1300|
|Ask||42.80 x 2900|
|Day's Range||42.19 - 43.20|
|52 Week Range||38.95 - 99.36|
|Beta (5Y Monthly)||2.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 16, 2021 - Feb 22, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||82.33|
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m. ET to review clinical data presented at the 62nd American Society of Hematology Annual Meeting and Exposition.
NEW YORK, NY / ACCESSWIRE / November 23, 2020 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc.
Atlanta, Georgia--(Newsfile Corp. - November 11, 2020) - Holzer & Holzer, LLC is investigating whether bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) complied with federal securities laws. On November 4, 2020, the Company announced its submission to the FDA for approval of its bb1111 product will be delayed until late 2022. The price of bluebird's stock fell following the announcement. If you purchased shares of bluebird and suffered a loss on ...